Use of idrabiotaparinux to decrease the incidence of haemorrhage during Antithrombotic Therapy

摘要

This refers to the use of idrabiotaparinux for Treatment and secondary prevention of thrombotic diseases, in which the use of idrabiotaparinux implies a decrease in the incidence of bleeding, particularly Massive Bleeding during the treatment.Claim 3: Use according to claim 1 or claim 2, in which Pathology is thrombotic Venous thromboembolism. The use according to claim 4: any of claims 1 to 3, in which Pathology is thrombotic Deep Venous Thrombosis.The use according to claim 5: any of claims 1 to 4, in which the drug is useful for the treatment of Venous thromboembolism and for the Prevention of venous thromboembolic events later.Claim 2: Use according to any of claims 1 to 5, in which the incidence of Bleeding is decreased in comparison with treatment by idraparinux or a Vitamin K antagonist.